{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"5"}]}],"title":"On-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"127"},{"groupId":"OG003","value":"57"}]}],"title":"Total deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"208"},{"groupId":"OG003","value":"98"}],"units":"Participants"}],"description":"Deaths on-treatment were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approximately 8 years.\n\nTotal Deaths were collected from first dose of study treatment until end of post-treatment survival follow, up to maximum duration of approximately 8 years.","groups":[{"description":"Participants received everolimus 10 mg once daily BSC throughout the study","id":"OG000","title":"Everolimus + BSC (Throughout the Study)"},{"description":"Participants who crossed over from placebo arm (blinded period) to open-label treatment with everolimus 10mg once daily plus BSC","id":"OG001","title":"Everolimus +BSC (Crossover)"},{"description":"All participants who received everolimus 10 mg once daily plus BSC (including those who received everolimus+BSC from start to end of the study and those who received everolimus+BSC after crossover)","id":"OG002","title":"Everolimus+BSC (All)"},{"description":"Participants received matching placebo once daily plus BSC during the blinded period","id":"OG003","title":"Placebo + BSC (Blinded Period)"}],"paramType":"NUMBER","populationDescription":"The safety set consists of all participants who received at least one dose of the study drug and had at least one post-baseline safety evaluation. Participants were analyzed according to treatment actually received: One participant randomized to everolimus arm received only placebo and therefore, appears in the placebo arm in the safety set","reportingStatus":"POSTED","timeFrame":"On-treatment deaths: up to approximately 8 years. All deaths: up to approximately 8 years","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}